CSMYF (COSMOS Pharmaceutical) YoY EBITDA Growth: 881.00% (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSMYF COSMOS Pharmaceutical Corp CSMYF
93 GF Score
Price $37.06
GF Value $51.95
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is COSMOS Pharmaceutical YoY EBITDA Growth?

COSMOS Pharmaceutical CSMYF 93 YoY EBITDA Growth is 881.00% as of Feb. 2026. GuruFocus rates CSMYF with a GF Score™ of 93/100 and a GF Value™ of $51.95 (Modestly Undervalued). The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. COSMOS Pharmaceutical's YoY EBITDA Growth for the quarter that ended in Feb. 2026 was 881.00%.

COSMOS Pharmaceutical's EBITDA per Share for the three months ended in Feb. 2026 was $0.98.

COSMOS Pharmaceutical YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for COSMOS Pharmaceutical's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

COSMOS Pharmaceutical YoY EBITDA Growth Chart

COSMOS Pharmaceutical Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.16 -2.12 -5.90 29.81 -2.00

COSMOS Pharmaceutical Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 333.65 -0.10 5.90 881.00 2.99
CSMYF
93GF Score
COSMOS Pharmaceutical Corp CSMYF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

COSMOS Pharmaceutical YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

COSMOS Pharmaceutical's YoY EBITDA Growth for the fiscal year that ended in May. 2026 is calculated as:

YoY EBITDA Growth (A: May. 2026 )
=(EBITDA per Share (A: May. 2026 )-EBITDA per Share (A: May. 2025 ))/ | EBITDA per Share (A: May. 2025 ) |
=(5.535-5.648)/ | 5.648 |
=-2.00 %

COSMOS Pharmaceutical's YoY EBITDA Growth for the quarter that ended in Feb. 2026 is calculated as:

YoY EBITDA Growth (Q: Feb. 2026 )
=(EBITDA per Share (Q: Feb. 2026 )-EBITDA per Share (Q: Feb. 2025 )) / | EBITDA per Share (Q: Feb. 2025 )) |
=(0.981-0.1)/ | 0.1 |
=881.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 881.00% mean?
COSMOS Pharmaceutical (CSMYF) has a YoY EBITDA Growth of 881.00% as of Feb. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for COSMOS Pharmaceutical and its competitors.
Is COSMOS Pharmaceutical's YoY EBITDA Growth too high?
COSMOS Pharmaceutical's current YoY EBITDA Growth is 881.00%. Overall, COSMOS Pharmaceutical has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does COSMOS Pharmaceutical's YoY EBITDA Growth compare to competitors?
COSMOS Pharmaceutical's YoY EBITDA Growth of 881.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for COSMOS Pharmaceutical and its competitors. COSMOS Pharmaceutical's current YoY EBITDA Growth is 881.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is COSMOS Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, COSMOS Pharmaceutical (CSMYF) is currently considered Modestly Undervalued. The stock's GF Value™ is $51.95, compared to a current price of $37.06 — trading 28.7% below its estimated fair value. The current YoY EBITDA Growth is 881.00%. COSMOS Pharmaceutical's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For COSMOS Pharmaceutical (CSMYF), the current YoY EBITDA Growth is 881.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is COSMOS Pharmaceutical (CSMYF) Overvalued in 2026?

Based on GuruFocus' analysis, COSMOS Pharmaceutical stock appears to be undervalued. The current stock price of $37.06 is trading 28.7% below its estimated GF Value™ of $51.95. GuruFocus considers COSMOS Pharmaceutical to be Modestly Undervalued.

Key valuation signals for CSMYF:

  • YoY EBITDA Growth: 881.00%
  • GF Value™: $51.95 vs. price of $37.06 (28.7% below fair value)
  • GF Score™: 93/100 with 2 warning signs

No single metric tells the full story. See the CSMYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

COSMOS Pharmaceutical Business Description

Other Exchanges 3349:Japan
Address 10-1 Hakataeki Higashi 2-chome, 4th floor, JR Hakata Station East NS Building S, Hakata-ku, Fukuoka Prefecture, Fukuoka, JPN, 812-0013
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company emphasizes convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. It also operates a private grocery brand called ON 365.
93GF Score

Get the complete analysis for CSMYF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.06
Price
$51.95
GF Value